Both authors have contributed equally to this study.
Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia
Article first published online: 28 MAR 2011
© 2011 John Wiley and Sons A/S
Volume 13, Issue 2, pages 198–207, March 2011
How to Cite
Müller, D. J., Zai, C. C., Shinkai, T., Strauss, J. and Kennedy, J. L. (2011), Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia. Bipolar Disorders, 13: 198–207. doi: 10.1111/j.1399-5618.2011.00905.x
The authors of this paper do not have any commercial associations that might pose a conflict of interest in connection with this manuscript.
- Issue published online: 28 MAR 2011
- Article first published online: 28 MAR 2011
- Received 19 October 2009, revised and accepted for publication 6 January 2011
- bipolar disorder;
- d-amino acid oxidase activator (DAOA/G72);
- family-based association test;
Müller DJ, Zai CC, Shinkai T, Strauss J, Kennedy JL. Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia. Bipolar Disord 2011: 13: 198–207. © 2011 The Authors. Journal compilation © 2011 John Wiley & Sons A/S.
Objective: The d-amino acid oxidase activator (DAOA, or G72) is involved in the oxidation of d-serine, an endogenous modulator of N-methyl-d-aspartate receptors and thus represents an important candidate in psychotic disorders. Several studies reported the DAOA/G72 gene to be associated with schizophrenia (SZ) and bipolar disorder (BD); however, the associated polymorphisms varied between SZ and BD. This study attempts to replicate the DAOA/G72 findings in BD and to conduct subgroup analyses based on the presence or absence of psychotic symptoms.
Methods: Five polymorphisms of the DAOA/G72 gene (rs1341402, rs1935062, rs2391191, rs947267, and rs778294) were analysed for association with BD in a family-based study design (303 core families including 916 individuals). We also conducted a meta-analysis of DAOA/G72 polymorphisms in BD and SZ.
Results: Marker rs1935062 was significantly associated with BD diagnosis in our sample (Z-score for C-allele = −2.33, p = 0.02, uncorrected for genome-wide multiple comparisons). When we examined the subset of BD patients with psychotic symptoms (157 families), no significant results were obtained. Our meta-analysis yielded negative findings for DAOA/G72 markers in BD and positive findings for marker rs2391191 in SZ in East Asians. However, significant heterogeneity across studies limits interpretation.
Conclusions: Our results provide evidence that suggests a possible role of the DAOA/G72 gene in BD and SZ. Marker rs1935062 may be specifically associated with BD, while marker rs2391191 may be associated with SZ but not with BD. Together with previous studies, these findings suggest that the DAOA/G72 gene confers susceptibility to both BD and SZ, but that different polymorphisms may potentially differentiate between these two disorders.